Christopher Lay, CEO of Marsh McLennan UK, William Thomas-Ferrand and Matthew Latham explain why they are backing the London Market Group’s captive initiative.
In this GCP Short, produced in partnership with MAXIS Global Benefits Network, we explore findings from the network's latest whitepaper on GLP-1s, often known as weight-loss drugs.
Richard is joined by Mat Robinson, Senior Managing Director and Captive Operations Leader, and Matt Gravelin, Managing Director in Consulting at Brown & Brown, to discuss how organisations can hone their captive strategy and achieve strong internal buy-in from across the group.
